Interaction of 8 He with 208Pb at near-barrier energies: 4 He and 6 He production

Spanish Ministry of Economy and Competitiveness-FPA-2010-22131-CO2-01 (FINURA) y FPA2013-47327-C2-1-RMinistry of Science and Higher Education of Poland-N202 033637National Science Centre of Poland-2013/08/M/ST2/00257 (LEA-COPIGAL) y 2014/14/M/ST2/00738 (COPIN-INFN Collaboration)European Science Foundation-EUI2009-04163432 (EUROGENESIS

Elastic scattering of 8He + 208Pb at 22MeV

The dynamics of 8He around the Coulomb barrier is investigated by measuring the energy and angular distribution of the elastic 8He and the 6He and 4He fragment yields in the collision process with a 208Pb target. The experiment was carried out at SPIRAL/GANIL in October 2010. The experimental results will provide information about the relevant reaction mechanisms and the validity of the optical model (OM) when applied to exotic nuclei. In this paper, details of the experimental setup and preliminary results on the elastic scattering for the collision at 22 MeV are presented.Spanish Research Council FPA-2010-22131-CO2-01Ministry of Science and Higher Education of Poland N202 03363

Scattering of 8He on 208Pb at Energies Around the Coulomb Barrier

We have measured the angular distributions of elastic scattering and 6,4He fragments produced in the collisions of an exotic beam of 8He on a 208Pb target at laboratory energies of 18 and 22 MeV, just around the Coulomb barrier (19 MeV). The measurements were performed at the SPIRAL/GANIL facility in Caen, France. In this paper, we present preliminary data on elastic cross sections and discuss the results using optical model and coupled reaction channel calculations.Spanish Research Council FPA-2010-22131-C02-01Ministry of Science and Higher Education of Poland No. N202 03363

Study of the near-barrier scattering of 8He on 208Pb

The structure and dynamics of 8He have been studied through the collision process with a 208Pb target at energies of 22 and 16 MeV, above and below the Coulomb barrier, respectively. The energy and angular distributions of the elastically scattered 8He and the 6,4He fragments were measured. In this paper, we discuss the method used to determine the effective position of the beam spot on the reaction target and the scattering and solid angles of each pixel of the detector array.Ministerio de Economía y Competitividad FPA2010-22131-C021-01, FPA2014-59954-C3-1-PMinistry of Science and Higher Education of Poland N202 033637European Science Foundation EUI2009-0416

Scattering of 8He on 208Pb at 22 MeV

The skin nucleus 8He is investigated by measuring the angular distribution of the elasticly scattered 8He and the 6,4He fragments produced in the collision with a 208Pb target at 22 MeV, just above the Coulomb barrier. The experiment was carried out at SPIRAL/GANIL in 2010. Here we present preliminary results for the elastic scattering

Near barrier scattering of 8He on 208Pb

The exotic nucleus 8He is investigated by means of the measurement of the angular distributions of the elastic channel and the 6He and 4He fragment yields produced in the collision with a 208Pb target at two energies around the Coulomb barrier, 16 and 22 MeV. The experiment was performed at the GANIL-SPIRAL facility, with the aim of extracting information about the structure of 8He and the relevant reaction mechanisms. In this contribution, details of the experimental setup and preliminary data on elastic cross sections are reporte

pilotSTRATEGY project 2021-2026: “CO2 Geological Pilots in Strategic Territories”

[EN] The pilotSTRATEGY (2021-2026) is investigating geological CO2 storage sites in industrial regions to support development of large-scale carbon capture and storage (CCS). It is focused on deep saline aquifers–porous rock formations filled with brine several kilometres below ground – which promise a large capacity for storing captured CO2. The goal of the characterisation is to assess the site’s containment, injectivity, capacity, integrity, hydrodynamics, and monitorability in order to ensure safe and permanent storage of CO2. PilotSTRATEGY covers the initial stages of project development up to the pre-final investment decision (pre-FID), regulatory approval and permitting of storage, and applied on selected structures of Paris Basin in France, the Lusitanian Basin in Portugal and the Ebro Basin in Spain, and in lower detail, in West Macedonia in Greece and Upper Silesia in Poland.The project has received funding from the European Union’s Horizon 2020 programme (10.1 million Euros, No. 101022664).Peer reviewe

Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections

IMPORTANCE The consumption of broad-spectrum drugs has increased as a consequence of the spread of multidrug-resistant (MDR) Escherichia coli. Finding alternatives for these infections is critical, for which some neglected drugs may be an option. OBJECTIVE To determine whether fosfomycin is noninferior to ceftriaxone or meropenem in the targeted treatment of bacteremic urinary tract infections (bUTIs) due to MDR E coli. DESIGN, SETTING, AND PARTICIPANTS This multicenter, randomized, pragmatic, open clinical trial was conducted at 22 Spanish hospitals from June 2014 to December 2018. Eligible participants were adult patients with bacteremic urinary tract infections due to MDR E coli; 161 of 1578 screened patients were randomized and followed up for 60 days. Data were analyzed in May 2021. INTERVENTIONS Patients were randomized 1 to 1 to receive intravenous fosfomycin disodium at 4 g every 6 hours (70 participants) or a comparator (ceftriaxone or meropenem if resistant; 73 participants) with the option to switch to oral fosfomycin trometamol for the fosfomycin group or an active oral drug or pa renteral ertapenem for the comparator group after 4 days. MAIN OUTCOMES AND MEASURES The primary outcome was clinical and microbiological cure (CMC) 5 to 7 days after finalization of treatment; a noninferiority margin of 7% was considered. RESULTS Among 143 patients in the modified intention-to-treat population (median [IQR] age, 72 [62-81] years; 73 [51.0%] women), 48 of 70 patients (68.6%) treated with fosfomycin and 57 of 73 patients (78.1%) treated with comparators reached CMC (risk difference, -9.4 percentage points; 1-sided 95% CI, -21.5 to infinity percentage points; P = .10). While clinical or microbiological failure occurred among 10 patients (14.3%) treated with fosfomycin and 14 patients (19.7%) treated with comparators (risk difference, -5.4 percentage points; 1-sided 95% CI. -infinity to 4.9; percentage points; P = .19), an increased rate of adverse event-related discontinuations occurred with fosfomycin vs comparators (6 discontinuations [8.5%] vs 0 discontinuations; P = .006). In an exploratory analysis among a subset of 38 patients who underwent rectal colonization studies, patients treated with fosfomycin acquired a new ceftriaxone-resistant or meropenem-resistant gram-negative bacteria at a decreased rate compared with patients treated with comparators (0 of 21 patients vs 4 of 17 patients [23.5%]; 1-sided P = .01). CONCLUSIONS AND RELEVANCE This study found that fosfomycin did not demonstrate noninferiority to comparators as targeted treatment of bUTI from MDR E coli; this was due to an increased rate of adverse event-related discontinuations. This finding suggests that fosfomycin may be considered for selected patients with these infections

EducaFarma 9.0

Memoria ID-020 Ayudas de la Universidad de Salamanca para la innovación docente, curso 2020-2021

Role of age and comorbidities in mortality of patients with infective endocarditis

[Purpose]: The aim of this study was to analyse the characteristics of patients with IE in three groups of age and to assess the ability of age and the Charlson Comorbidity Index (CCI) to predict mortality. [Methods]: Prospective cohort study of all patients with IE included in the GAMES Spanish database between 2008 and 2015.Patients were stratified into three age groups:<65 years,65 to 80 years,and ≥ 80 years.The area under the receiver-operating characteristic (AUROC) curve was calculated to quantify the diagnostic accuracy of the CCI to predict mortality risk. [Results]: A total of 3120 patients with IE (1327 < 65 years;1291 65-80 years;502 ≥ 80 years) were enrolled.Fever and heart failure were the most common presentations of IE, with no differences among age groups.Patients ≥80 years who underwent surgery were significantly lower compared with other age groups (14.3%,65 years; 20.5%,65-79 years; 31.3%,≥80 years). In-hospital mortality was lower in the <65-year group (20.3%,<65 years;30.1%,65-79 years;34.7%,≥80 years;p < 0.001) as well as 1-year mortality (3.2%, <65 years; 5.5%, 65-80 years;7.6%,≥80 years; p = 0.003).Independent predictors of mortality were age ≥ 80 years (hazard ratio [HR]:2.78;95% confidence interval [CI]:2.32–3.34), CCI ≥ 3 (HR:1.62; 95% CI:1.39–1.88),and non-performed surgery (HR:1.64;95% CI:11.16–1.58).When the three age groups were compared,the AUROC curve for CCI was significantly larger for patients aged <65 years(p < 0.001) for both in-hospital and 1-year mortality. [Conclusion]: There were no differences in the clinical presentation of IE between the groups. Age ≥ 80 years, high comorbidity (measured by CCI),and non-performance of surgery were independent predictors of mortality in patients with IE.CCI could help to identify those patients with IE and surgical indication who present a lower risk of in-hospital and 1-year mortality after surgery, especially in the <65-year group